Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 0962 • ACR Convergence 2021
Association of Antiphospholipid Antibodies with Thromboembolic Events and Severe Outcomes in COVID-19
Arielle Mendel¹, Marvin Fritzler², Yvan St.Pierre¹, Joyce Rauch³, Sasha Bernatsky³ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although several studies indicate that patients with COVID-19 produce antiphospholipid antibodies (aPL), it is unclear which aPL subtype predominates and whether aPL correlates with…
Abstract Number: 1513 • ACR Convergence 2021
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
Ryosuke Hiwa¹, Hailyn Nielsen¹, James Mueller¹ and Julie Zikherman², ¹University of California San Francisco, San Francisco, CA, ²UCSF Medical Center, San Francisco, CA
Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
Abstract Number: 1078 • ACR Convergence 2020
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
Antonella Notarnicola¹, Charlotta Preger², Susanna L. Lundström², Nuria Renard², Edvard Wigren², Eveline Van Gompel², Angeles S. Galindo-Feria², Helena Persson³, Maryam Fathi⁴, Johan Grunewald², Per-Johan Jakobsson², Susanne Gräslund², Ingrid Lundberg⁵ and Cátia Fernandes-Cerqueira², ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Karolinska Institutet, stockholm, Sweden, ³Science for Life Laboratories, KTH, Stockholm, Sweden, ⁴Karolinska University Hospital, stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…
Abstract Number: 1500 • ACR Convergence 2020
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Deborah Friedman¹, Mimi Kim², Nathalie Costedoat-Chalumeau³, Robert Clancy⁴, Joshua Copel⁵, Colin Phoon⁶, Bettina Cuneo⁷, Rebecca Cohen⁶, Mala Masson⁶, Benjamin Wainwright⁶, Noel Zahr⁸, Amit Saxena⁴, Peter Izmirly⁹ and Jill Buyon¹⁰, ¹New York Medical College, Valhalla, ²Albert Einstein College of Medicine, Bronx, ³APHP, Université de Paris, Paris, France, ⁴NYU School of Medicine, New York, ⁵Yale School of Medicine, New Haven, ⁶New York University School of Medicine, New York, ⁷University of Colorado School of Medicine, Aurora, ⁸Pitié-Salpêtrière University Hospital, Paris, France, ⁹Department of Medicine, New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. …
Abstract Number: 1917 • ACR Convergence 2020
In Myositis Patients, Sjögren’s Syndrome Is Associated with Inclusion Body Myositis and with anti-cN1A Antibody Independently of the Myositis Subgroups
Dan Lévy¹, Benoit Nespola², Margherita Giannini³, Renaud Felten⁴, Francois Severac³, Coralie Varoquier³, Marina Rinagel³, Anne-Sophie Korganow⁵, Vincent Poindron⁵, Thierry Martin⁵, Julien Campagne⁶, Hassam Chereih⁷, Bastien Bouldoires⁸, Baptiste Hervier⁹, Cédric Lenormand³, Emmanuel Chatelus³, Laurent Arnaud¹⁰, Bernard Gény³, Jean Sibilia⁴, Jacques-Eric Gottenberg¹¹ and Alain Meyer¹², ¹CHU Strasbourg, CH, ²Department of Immunobiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³CHU Strasbourg, Strasbourg, ⁴Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ⁵Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁶Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ⁷CH Pontarlier, Pontarlier, ⁸HP Colmar, Colmar, ⁹APHP Paris, Paris, ¹⁰Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, ¹¹Strasbourg University Hospital, Strasbourg, France, ¹²Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France
Background/Purpose: Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according…
Abstract Number: 0242 • ACR Convergence 2020
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
Majed Albirdisi¹, David d'Cruz², Shirish Sangle² and Natasha Jordan³, ¹King Fahad Medical City, riyadh, Saudi Arabia, ²guys and st thomas hospital, london, United Kingdom, ³addebrooke's hospital, cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
Abstract Number: 0775 • ACR Convergence 2020
T and B Cell Responses to Common Tenascin-C Peptides in RA
JING Song¹, Anja Schwenzer², Sara Turcinov³, Alicia Wong², Cliff Rims¹, Lorena Rodriguez Martinez², David Arribas-Layton⁴, Christina Gerstner⁵, Virginia Muir⁶, Jeffrey Carlin⁷, Kim Midwood², Vivianne Malmström⁸, Eddie James¹ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁴Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, ⁵Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Dmitriy Cherny¹ and Carrie Richardson¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
Abstract Number: 2039 • ACR Convergence 2020
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Britany Adler¹, Ami Shah², Francesco Boin³, Paul Wolters³, Livia Casciola-Rosen⁴ and Antony Rosen¹, ¹Johns Hopkins University, baltimore, MD, ²Johns Hopkins University School of Medicine, Ellicott City, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Johns Hopkins University, Johns Hopkins University, MD
Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
Abstract Number: 0251 • ACR Convergence 2020
Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic Lupus Erythematosus Cohort
May Choi¹, Marvin Fritzler², Karen Costenbader³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St. Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Díaz⁹, F Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul Fortin¹⁶, Dafna Gladman¹⁷, Ian Bruce¹⁸, Michelle Petri¹⁹, Ellen M Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jönsen²⁴, Graciela Alarcón²⁵, Ronald F Van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁸, Guillermo Ruiz-Irastorza²⁹, S. Sam Lim³⁰, Murat Inanc³¹, Kenneth Kalunian³², Søren Jacobsen³³, Christine Peschken³⁴, Diane Kamen³⁵, Anca Askanase³⁶ and Ann Clarke³⁷, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷McGill University, Montreal, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ¹²Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹³Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, ²⁰SUNY Downstate Health Sciences University, Brooklyn, ²¹University of North Carolina, Chapel Hill, NC, ²²Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²³Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Lund University, Lund, Sweden, ²⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Feinstein Institute for Medical Research, Manhasset, NY, ²⁹Hospital Universitario Cruces, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³²University of California San Diego, La Jolla, CA, ³³University of Copenhagen, Copenhagen, Denmark, ³⁴Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³⁵Medical University of South Carolina, Charleston, SC, ³⁶Columbia University College of Physicians and Surgeons, New York, NY, ³⁷University of Calgary, Calgary, Canada
Background/Purpose: ANA testing as an approach to diagnosing and classifying SLE, now embedded in the EULAR/ACR Criteria, is more important than ever. Cross-sectional studies indicate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].